Volver a la clasificación

GE HealthCare Technologies Inc. (GEHC)

Valor Justo
HealthcareMedical DevicesUnited States

Fundamental

54

Precio

$64.63

Capitalización Bursátil

$30.20B

Parte 1 · Cuánto vale la empresa

Resumen

GE HealthCare makes the diagnostic imaging equipment hospitals use to see inside the body — MRI, CT, X-ray, ultrasound and PET scanners — plus the contrast agents and radioactive tracers that make those scans clearer and the monitors and ventilators used to track patients at the bedside. Spun off from General Electric in 2023, it sells mainly to hospitals and health systems worldwide, competing in a market shared by a small number of large, similarly capable equipment makers.

Cómo genera ingresos

Revenue mixes large, lumpy equipment sales — an MRI or CT scanner can cost hospitals millions of dollars — with recurring, higher-margin revenue from service contracts, software and the imaging agents and tracers that must be repurchased for every scan. Equipment sales depend on hospital capital budgets and can be deferred, while service and consumable revenue is stickier once a machine is installed. AI-enabled software features are an increasing share of what GE HealthCare sells alongside the hardware.

Ingresos por segmento

Advanced Imaging Solutions70.78%

MRI, CT, X-ray, ultrasound and PET imaging equipment plus the advanced visualization software used to interpret the images.

Patient Care Solutions14.96%

Patient monitors, ventilators, anesthesia delivery and other equipment used to track and support patients at the bedside.

Pharmaceutical Diagnostics14.06%

Contrast agents and radioactive tracers injected into patients to make imaging scans clearer and diagnoses more precise.

Other0.19%

Financial services supporting equipment leasing and purchases, a small residual outside the three main product lines.

Ventaja competitiva

Costes de cambio · Estrecha

Hospitals that buy a GE HealthCare scanner also commit to years of service contracts, staff training and integration with existing IT systems, making a switch to a rival brand costly and disruptive. That lock-in supports recurring service and consumables revenue, but Siemens Healthineers and Philips offer comparably capable equipment, so hospitals do switch brands at each new purchase cycle.

Qué impulsa la demanda

Moderadamente cíclico

Healthcare spending overall is fairly defensive, but big-ticket imaging equipment purchases are capital decisions hospitals can postpone when budgets tighten or interest rates rise, unlike the recurring consumables and service revenue tied to machines already installed. Aging populations and rising diagnostic scan volumes support long-term demand, while hospital reimbursement and capital-spending cycles create shorter-term swings.

Riesgos clave

  • Hospital capital spending cycles — Large equipment purchases can be postponed when hospital budgets tighten or financing costs rise, creating lumpy order flow that does not track the steadier growth of the underlying diagnostics market.
  • Spin-off leverage — GE HealthCare took on new debt as part of its 2023 separation from General Electric; that leverage leaves less room to absorb a downturn or fund acquisitions than a business with a cleaner balance sheet.
  • Competition from Siemens Healthineers and Philips — Both rivals sell comparably capable imaging and patient-monitoring equipment, and hospitals routinely evaluate all major vendors at each replacement cycle, limiting GE HealthCare's pricing power.
  • Regulatory and product approval risk — Medical devices, imaging agents and radiopharmaceuticals require regulatory clearance in every market sold; delays, recalls or stricter rules can push back launches or force costly remediation.

Concentración de clientes

GE HealthCare sells to thousands of hospitals and health systems across more than 100 countries, so no single customer accounts for a material share of revenue.

Los argumentos a favor

Buyers argue that GE HealthCare's installed base of imaging equipment across thousands of hospitals generates durable, high-margin recurring service and consumables revenue, and that aging populations and expanding diagnostic and AI-enabled software use support years of underlying growth.

Los argumentos en contra

Sellers fear that big-ticket equipment sales are exposed to hospital capital-spending cuts, that debt taken on at the 2023 spin-off limits financial flexibility, and that Siemens Healthineers and Philips can match GE HealthCare's technology closely enough to keep pricing power in check.

Written by the editors, published on 18 de agosto de 2026

Direct competitors

Who this company fights with for the same customers

Generated on 18 de septiembre de 2026 with claude-haiku-4-5 — shared with all users

Siemens Healthineers AGSHL

GE HealthCare's 10-K names it a primary global competitor: the two sell the same CT, MRI, X-ray, molecular imaging and ultrasound systems, plus service contracts, to the same hospitals and imaging centres worldwide.

Koninklijke Philips N.V.PHIA

Named in the 10-K as a primary competitor: Philips bids against GE HealthCare on imaging systems, ultrasound and above all on hospital patient monitoring, the heart of GE's Patient Care Solutions segment.

Canon Inc. (キヤノン株式会社)7751

Through its Canon Medical Systems subsidiary, named in GE HealthCare's 10-K, it sells competing CT, MRI, X-ray and ultrasound systems to the same hospital buyers, pushing hard on mid-range price-performance.

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (深圳迈瑞生物医疗电子股份有限公司)300760

Named in the 10-K, Mindray competes directly for the same patient-monitoring, anaesthesia and ultrasound budgets, and has become the volume alternative in China and other emerging markets.

Shanghai United Imaging Healthcare Co., Ltd. (上海联影医疗科技股份有限公司)688271

Also named in the 10-K, it sells high-specification CT, MRI and PET systems at lower prices, taking imaging tenders from GE HealthCare first in China and increasingly abroad.

Bayer AGBAYN

In the Pharmaceutical Diagnostics segment, the 10-K names Bayer as a direct rival: both supply the contrast media injected during CT and MRI scans, sold to the same hospitals and radiology chains.

Balance y Liquidez

Ingresos

$20.98B

Últimos 12 meses (hasta 31/3/2026)

Beneficio Neto

$1.91B

Últimos 12 meses (hasta 31/3/2026)

Flujo de Caja Libre

$1.50B

Patrimonio Neto Total

$10.38B

Pasivo Total

$26.31B

Ratio de Liquidez

1.22

Cobertura de Intereses

-

Deuda/EBITDA

2.94

Beneficio Por Acción

Ingresos y Beneficio Neto

Flujo de Caja Libre

Desglose de Ingresos

Estado histórico

Márgenes en el tiempo

La deuda en el tiempo

Cuánto pesa la deuda

Cuadro de crecimiento

Crecimiento — Ingresos

Estimación de Valor Justo

Caso generalValoración Justa

Valor Justo

$63.46

Precio Actual

$64.63

Margen de Seguridad

-1.8%

Rango de Valor Justo

$47.93 - $78.98

Dispersión entre los métodos de valoración utilizados, no un intervalo de confianza calibrado estadísticamente.

Métodos de Estimación

Precio objetivo de los analistas:$83.05
Flujo de caja descontado (DCF):$60.39
Múltiplo sobre beneficios (P/E):$54.48
Fórmula de crecimiento de Graham:$32.46
Valor de la capacidad de generar beneficios (EPV):$52.21
P/B justificado:$66.33
Descuento de dividendos (Gordon):$2.85
P/FFO, fondos de operaciones:Datos insuficientes para calcularlo
Beneficios de mitad de ciclo:$120.76
Múltiplo sobre ingresos:$183.85
Consenso de Analistas:Comprar (19B / 9H / 0S)
Última Sorpresa de Resultados:+7.03%

Métricas de Valoración

Ratio P/E

15.34

ROE

20.1%

Ratio P/B

2.73

P/FCF

19.16

Margen Bruto

39.1%

ROIC

7.3%

Radar de Rentabilidad

Creación de Valor (Ventaja Competitiva)

ROIC

7.3%

WACC

6.7%

ROIC − WACC

+0.6 pp

El ROIC está en línea con el coste del capital: la empresa apenas cubre su coste de capital.

Criterios de Análisis Fundamental

Superado (15)

  • ROIC 7.3%
  • Gross Margin 39.1%
  • P/FCF 19.16
  • P/B Ratio 2.73
  • Debt/Equity ratio
  • Operating Margin 12.6%
  • Positive Free Cash Flow
  • Current Ratio
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 18.9%
  • Analyst Consensus 68% Buy
  • Earnings Quality (OCF/NI) 1.06
  • Share Dilution -0.3%
  • Piotroski F-Score 5/9

Fallido (10)

  • EPS shows upward trend
  • EPS CAGR -2.08%
  • Price CAGR 3.15%
  • CapEx intensity
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Fairly valued)
  • Revenue Growth 5Y 3.7%
  • Earnings Surprise avg 0.1%
  • Net Margin Trend 9.1% vs 11.0%

No disponible (3)

  • Dividend Payout NaN%
  • Interest Coverage
  • PEG Ratio (need PE > 0 and growth > 0)

Piotroski F-Score

5/9

Señales mixtas: algunas áreas requieren atención

score
criteria

Calidad de los Beneficios

1.06

Alta calidad: beneficios respaldados por efectivo

Dilución de Acciones

-0.3%

Recomprando acciones. Favorable para el accionista

Participaciones institucionales

Gobernanza

Equipo Directivo

NombreCargoEdad
Mr. Peter J. ArduiniPresident, CEO & Director60
Dr. Taha Kass-Hout M.D., M.S.Chief Science & Technology Officer53
Mr. Frank R. Jimenez Esq.General Counsel & Corporate Secretary60
Ms. Jeannette BankesPresident & CEO of Patient Care Solutions54

Riesgo de Auditoría

1

Riesgo del Consejo

5

Riesgo de Compensación

5

Riesgo de Derechos del Accionista

5

Parte 2 · El precio y el momento de entrar

Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.

Documentos

  • Informe anual (10-K)

    Un resumen anual del negocio, los resultados financieros y los riesgos de la empresa.

    Presentado el 2026-02-04

    Ver documento
  • Informe trimestral (10-Q)

    Una actualización del desempeño financiero de los últimos tres meses.

    Presentado el 2026-07-29

    Ver documento
  • Informe de hecho relevante (8-K)

    Un aviso sobre un hecho relevante, como un cambio de dirección o un anuncio importante.

    Presentado el 2026-09-22

    Ver documento

via SEC EDGAR

Historial de Resultados

via SEC EDGAR

Latest News

Recent headlines for GEHC, sourced from Markets Gazette.

  • 29d agoNEGATIVE
    These stocks in the red-hot healthcare sector have gotten too crowded to own

    Analysts are recommending an options strategy to bet against GE HealthCare, citing that the stock has become too crowded with bullish positions. This suggests a potential for a sharp reversal if sentiment shifts or if the company fails to meet elevated expectations. The crowded nature of the trade implies that many investors have already piled into the healthcare stock, increasing the risk of a significant sell-off. For investors, this signals a potential downside risk and a need for caution in the short term.

via Markets Gazette